Abstract: The present invention relates to formulations and their use to treat ocular disorders such as uveitis. Particularly, the invention relates to a formulation comprising mycophenolic acid (MPA) or a pharmaceutically acceptable salt or derivative thereof; and at least one component selected from the group consisting of preservative, chelating agent, buffering agent, pH modifier, thickening agent, viscosity enhancer or viscosity modifier, antioxidant, tonicity modifier, surfactant, humectant, solvent or co-solvent, emulsifier, co-emulsifier, ointment base, targeting agent, polymer, wetting agent, lubricating agent, suspending agent, and therapeutic agent. The disclosure further provides preparation method of said ophthalmic formulations, a pharmaceutical kit comprising said formulations, and method for treating ocular diseases by administering said formulations.

Abstract: The present disclosure is in the field of polymers and pharmaceuticals/antimicrobials. The disclosure provides compounds based on SNAP (synthetic novel antimicrobial polymer) technology, compositions and methods of managing microbial infections including surgical site infections (SSIs). The present compounds are used as a management/therapeutic strategy to target microbial infections and have advantages including excellent antimicrobial potency, biofilm disruption ability, broad spectrum activity against various organisms covering both gram negative and gram positive bacteria as well as fungal pathogens, and low toxicity profile to ensure a healthy therapeutic window for use in humans.

Abstract: The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Abstract: The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Abstract: The present invention relates to the field of antimicrobials and pharmaceutical sciences. The invention provides anti-fungal compositions for the management of fungal growth and treatment of fungal infections, including treatment of resistant fungal infections. The present compositions comprise at least one antifungal agent and at least one medium-chain saturated or unsaturated fatty acid having carbon chain length of C-1 to C-14 or ester thereof, optionally along with excipient(s), giving rise to a synergistic antifungal activity.

Abstract: The present disclosure relates to method for detecting P. acnes as well as a method for detecting mutation in genomic sequence of 23S rRNA sequence of P. acnes, particularly mutation A2058G. The method comprises amplifying a region of 23S rRNA specific for P. acnes using primers of SEQ ID Nos. 1 and 2 followed by detecting the mutation through selective action of an endonuclease- at a mismatch at the site of said mutation or post-hybridization with specific P. acnes 23S regions followed by mismatch specific endonuclease action. The presence of A2058G mutation confers antibiotic resistance, particularly clindamycin and erythromycin resistance, and thus the present disclosure also relates to methods of treating acne caused by clindamycin resistant P. acnes by using fluoroquinolone based antibiotics.

Abstract: The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.